Enteric-coated formulation of Myfortic reduces GI disorders

Published: 2008-06-16 06:59:00

Updated: 2008-06-16 06:59:00

In a new multicenter study, kidney transplant physicians reported a significant reduction in the incidence and symptom severity of gastrointestinal (GI) complications after conversion from MMF to enteric-coated Myfortic (mycophenolic acid), Novartis’s immunosuppressive agent for transplanted pati...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK